People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...